The DOI matches its Crossref record; 220 of the 220 references it cites were found in a registry or an index.
Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease
Abstract
Introduction For decades, the first-line treatment for kidney protection in people with type 1 diabetes (T1D) and chronic kidney disease (CKD) has been limited to intensive glycemic control, renin-angiotensin system blockers and managing modifiable risk factors. Accordingly, risk of CKD progression has remained unacceptably high, emphasizing the need for novel kidney protective therapies in T1D. Areas covered This review summarizes the recent evidence supporting the use of existing treatments used for kidney protection in people with type 2 diabetes (T2D) for potential repurposing for people with T1D. First, we highlight the putative structural and functional changes that actively contribute to CKD progression and highlight key hemodynamic, pro-inflammatory, and kidney injury risk markers in T1D. Next, we discuss emerging nephroprotective therapies targeting these pathophysiological factors, review mechanistic studies that have assessed kidney benefits of these agents in T1D, and highlight ongoing kidney-focused trials in T1D, including SUGARNSALT (NCT06217302), FINE-ONE (NCT05901831) and REMODEL-T1D (NCT05822609). Expert opinion Several medications have become available that could potentially transform CKD care in T1D. It is essential to devise strategies that could address the treatment landscape for kidney protection in T1D by assessing the risk-benefit calculus and expanding the nephrologist's toolkit for minimizing kidney risk in T1D.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“while current evidence of kidney benefit is limited to CKD in type 2 diabetes, multiple studies are in progress to determine if these therapies also improve kidney outcomes in people with type 1 diabetes (149,150).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [149]
Citations
Cites
Items 201–220 of 220
STOUGAARD, E. B., Kristensen, P. L., Kielgast, U. L., Andersen, H. U., Hamid, Y. H., Gæde, P., Søndergaard, E., Dørflinger, G. H., Fjeldborg, K., Hansen, K. W., et al. (2022) · Diabetes and Vascular Disease Research · doi:10.1177/14791641221130043 · Cited by 14
Self-citationPopovic, D. S., Karakasis, P., Koufakis, T., Fragakis, N., Παπάνας, Ν., Mitrović, M., Gouveri, E., & Patoulias, D. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155791 · Cited by 13
Schjoedt, K. J., Christensen, P., Jorsal, A., Boomsma, F., Rossing, P., & Parving, H. (2009) · Nephrology, Dialysis and Transplantation · doi:10.1093/ndt/gfp311 · Cited by 12
SGLT2 inhibitors and renal complications in type 1 diabetes
Petrie, J. R. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30311-9 · Cited by 11
Kugathasan, L., Sridhar, V. S., Tommerdahl, K. L., Xu, C., Bjornstad, P., Advani, A., & Cherney, D. Z. I. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155785 · Cited by 11
Self-citationDena, M., Svensson, A., Eeg-Olofson, K., Young, L., Carlson, A. L., Miller, K. M., Grimsmann, J. M., Welp, R., Mader, J. K., Maahs, D. M., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01169-w · Cited by 10
Perkins, B. A., Bebu, I., Gao, X., Karger, A. B., Hirsch, I. B., Karanchi, H., Molitch, M. E., Zinman, B., Lachin, J. M., & de Boer, I. H. (2022) · Diabetes Care · doi:10.2337/dc21-1883 · Cited by 9
Progression and regression of kidney disease in type 1 diabetes
Sigfrids, F. J., & Groop, P. (2023) · Frontiers in Nephrology · doi:10.3389/fneph.2023.1282818 · Cited by 9
Mineralocorticoid receptor overactivation in diabetes mellitus: role of O-GlcNAc modification
Jo, R., Itoh, H., & Shibata, H. (2024) · Hypertension Research · doi:10.1038/s41440-024-01734-3 · Cited by 9
Jiménez, D. L., Sridhar, V. S., Mendoza, M. L., Scholtes, R. A., Schmieder, R. E., Cherney, D. Z. I., van Raalte, D. H., Prieto, F. J. T., Miramontes‐González, J. P., & van Bommel, E. J. M. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae370 · Cited by 9
Self-citationKugathasan, L., Sridhar, V. S., Lytvyn, Y., Lovblom, L. E., Perkins, B. A., Advani, A., & Cherney, D. Z. I. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111764 · Cited by 8
Self-citationNewsholme, P., Keane, K. N., de Bittencourt, P. I. H., & Krause, M. D. S. (2013) · InTech eBooks · doi:10.5772/55349 · Cited by 7
Kugathasan, L., Dutta, P., Nardone, M., Sridhar, V. S., Campbell, D. J. T., Layton, A. T., Perkins, B. A., Barbour, S. J., Lam, T. K. T., Levin, A., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2840 · Cited by 5
Self-citationFinerenone’s Promise in Heart Failure and Kidney Disease
Shokri, K., Mohammadi, A., Karimian, A., Adeel, M. Y., Mozaffari, M. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000958 · Cited by 4
FP117SAFETY AND EFFICACY OF BARDOXOLONE METHYL IN PATIENTS WITH RARE CHRONIC KIDNEY DISEASES
Pérgola, P. E., Acharya, A., Appel, G. B., Awad, A., Betts, J. A., Block, G. A., Chin, M. P., Goldsberry, A., Inker, L. A., Meyer, C. J., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz106.fp117 · Cited by 3
Enhanced Intrarenal pro-renin and salt sensitive hypertension in a mouse model of Type-1 diabetes
Méndez, M., Ortiz-Capisano, C., Liao, J., & Liao, T. (2023) · Physiology · doi:10.1152/physiol.2023.38.s1.5735218 · Cited by 1
Khan, Z., Mauer, M. S., & Caramori, M. L. (2023) · Endocrines · doi:10.3390/endocrines4030039 · Cited by 1
Effects of Sotagliflozin on Anemia in Patients with Type 2 Diabetes (T2D) and Stages 3 and 4 CKD
Sridhar, V. S., Davies, M. J., Banks, P. L., Girard, M., Carroll, A. K., & Cherney, D. Z. I. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.20233411s1855a · Cited by 1
Self-citationNardone, M., Kugathasan, L., Sridhar, V. S., Dutta, P., Campbell, D. J. T., Layton, A. T., Perkins, B. A., Barbour, S. J., Lam, T. K. T., Levin, A., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.2024s5r4rxwp · Cited by 1
Self-citationEfficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD
Sridhar, V. S., Odutayo, A., Garg, S. K., Danne, T., Doria, A., Mauer, M. S., Davies, M. J., Banks, P. L., Girard, M., & Cherney, D. Z. I. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.20233411b13c · Cited by 1
Self-citation
Research works printed but not linked: 1
- 10.1016/j.jdiacomp.2021.107880 · DOI
Cited by
Sorted by citations
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 108
Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease
Caramori, M. L., REPETTO, E., Perkins, C., Pandey, A., & Rossing, P. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70640 · Cited by 4
Butler, J., Jamil, A., Cherney, D. Z. I., Jafar, T. H., Testani, J. M., & Khan, M. S. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag426 · Cited by 1
Self-citationKiernan, E. A., & de Boer, I. H. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0009
Current State of Cardiorenal Disease in People with Type 1 Diabetes
Fernandes, S., Hettinger, B., Ang, L. P., & Pop‐Busui, R. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.004
Metadata
- Authors
- Kugathasan, L., Aronson, Y., Sridhar, V. S., Ni, H., Ouimet, J.-P., Limonte, C. P., Sarma, S., & Cherney, D. Z. I.
- Affiliations
- University Health Network (CA)
- McGill University (CA)
- University of Washington (US)
- University of Toronto (CA)
- Corresponding author
- Cherney, David Z. I.
- ORCID
- Venue
- Expert Review of Clinical Immunology
- Publisher
- Informa UK Limited
- Published
- 2025-07-24
- Volume
- 21
- Issue
- 8
- Pages
- 1113-1134
- ISSN
- 1744-666X (ISSN-L)
- 1744-8409
- OpenAlex
- W4412557969
- Cited by
- 9
- References
- 220
- Citations by year
- 2026: 8 · 2025: 1
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- type 1 diabetes, chronic kidney disease, renal protection, nephroprotective therapy, drug repurposing, type 2 diabetes, chronic kidney disease progression, renin-angiotensin system inhibitors, inflammation, hemodynamics
- MeSH terms
- Animals, Clinical Trials as Topic, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Humans, Hypoglycemic Agents, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
